AllianceBernstein Holding Says AB Science Announced Masitinib Phase 2B/3 Study (AB12003) In Metastatic Castrate-Resistant Prostate Cancer Met Predefined Primary Endpoint
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint